Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

AlvotechNASDAQ: ALVO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $46.09M fell 29.6% year over year, behind the -6.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 24.8% from the prior quarter. Over 3 fiscal years it compounded at +54.3% a year.

Context

  • Cost of revenue amounted to 40.2% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -29.6% toward the trailing-twelve-month pace of -6.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$46.09M-24.8% QoQ
Last fiscal yearDec 2025
$235.56M+27.1% YoY
LTMMar 2026
$216.2M-6.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.6%——
1 year+27.1%——
3-year CAGR+54.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
235.56M USD
Year-over-year change
+27.1%

Cost of Revenue vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 cost of revenue of $216.2M is the 9th highest of the 11 companies compared; the peer median is $2.12B.
  • Its year-over-year change of -6.3% is the 10th highest of 11, against a peer median of +8.9%.
  • Cost of revenue amounts to 38.6% of revenue for ALVO, versus a peer median of 42.3%.
ALVO Competitors Peer median
Cost of Revenue for ALVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMGNAmgen Inc.LTM Jun 2026$10.43B -15.9%+18.8%27.3%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$8.23B -1.8%+1.5%47.5%
BIIBBiogen Inc.LTM Jun 2026$3.21B +17.0%+8.3%32.3%
OGNOrganon & Co.LTM Sep 2026$2.84B +0.3%+7.6%46.6%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$2.35B +14.7%+7.2%15.1%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$1.89B +6.4%+9.8%60.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$379.4M +5.6%+13.3%52.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$313.15M +11.4%+7.6%39.3%
ALVOAlvotechLTM Mar 2026$216.2M -6.3%+54.3%38.6%
HROWHarrow Health, Inc.LTM Mar 2026$69.57M +28.3%+38.8%25.9%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$39.32M +96.0%+75.1%45.2%
Peer median (excluding ALVO) $2.12B+8.9%+9.1%42.3%

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.77M83.03M91.43M489.68M586.32M
Cost of Revenue064.1M160.86M185.31M235.56M
Gross Profit36.77M18.93M(69.42M)304.37M350.76M
Gross Margin100.0%22.8%-75.9%62.2%59.8%
Research & Development191.01M180.62M210.83M171.31M184.19M
Selling, General & Admin84.13M186.74M73.04M61.45M90.95M
Operating Expenses272.23M365.38M285.44M234.73M272.56M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
EBITDA(18.03M)(439.8M)(493.67M)(32.28M)323.39M
EBITDA Margin-49.0%-529.7%-539.9%-6.6%55.2%
Operating Income(235.46M)(346.44M)(354.86M)69.64M78.21M
Operating Margin-640.3%-417.3%-388.1%14.2%13.3%
Interest Income19K912K4.82M4.62M198.49M
Interest Expense112.97M91.44M134.82M157.6M149.19M
Other Income / Expenses86.26M(205.21M)(296.19M)(287.21M)58.14M
Income Before Tax(149.2M)(551.65M)(651.05M)(217.56M)136.35M
Pre-Tax Margin-405.7%-664.4%-712.0%-44.4%23.3%
Income Tax Expense(47.69M)(38.07M)(99.32M)14.3M108.43M
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Net Margin-276.0%-618.6%-603.4%-47.3%4.8%
EPS (Basic)(3.25)(2.60)(2.43)(0.87)0.10
EPS (Diluted)(3.25)(2.60)(2.43)(0.87)0.10
Weighted Avg Shares31.25M197.72M227.26M267.92M279.19M
Weighted Avg Shares (Diluted)31.25M197.72M227.26M267.92M279.19M

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.